G-protein-coupled receptor 40 agonist GW9508 potentiates glucose-stimulated insulin secretion through activation of protein kinase Cα and ε in INS-1 cells.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 26 05 2018
accepted: 23 08 2019
entrez: 10 9 2019
pubmed: 10 9 2019
medline: 7 3 2020
Statut: epublish

Résumé

The mechanism by which G-protein-coupled receptor 40 (GPR40) signaling amplifies glucose-stimulated insulin secretion through activation of protein kinase C (PKC) is unknown. We examined whether a GPR40 agonist, GW9508, could stimulate conventional and novel isoforms of PKC at two glucose concentrations (3 mM and 20 mM) in INS-1D cells. Using epifluorescence microscopy, we monitored relative changes in the cytosolic fluorescence intensity of Fura2 as a marker of change in intracellular Ca2+ ([Ca2+]i) and relative increases in green fluorescent protein (GFP)-tagged myristoylated alanine-rich C kinase substrate (MARCKS-GFP) as a marker of PKC activation in response to GW9508 at 3 mM and 20 mM glucose. To assess the activation of the two PKC isoforms, relative increases in membrane fluorescence intensity of PKCα-GFP and PKCε-GFP were measured by total internal reflection fluorescence microscopy. Specific inhibitors of each PKC isotype were constructed and synthesized as peptide fusions with the third α-helix of the homeodomain of Antennapedia. At 3 mM glucose, GW9508 induced sustained MARCKS-GFP translocation to the cytosol, irrespective of changes in [Ca2+]i. At 20 mM glucose, GW9508 induced sustained MARCKS-GFP translocation but also transient translocation that followed sharp increases in [Ca2+]i. Although PKCα translocation was rarely observed, PKCε translocation to the plasma membrane was sustained by GW9508 at 3 mM glucose. At 20 mM glucose, GW9508 induced transient translocation of PKCα and sustained translocation as well as transient translocation of PKCε. While the inhibitors (75 μM) of each PKC isotype reduced GW9508-potentiated, glucose-stimulated insulin secretion in INS-1D cells, the PKCε inhibitor had a more potent effect. GW9508 activated PKCε but not PKCα at a substimulatory concentration of glucose. Both PKC isotypes were activated at a stimulatory concentration of glucose and contributed to glucose-stimulated insulin secretion in insulin-producing cells.

Identifiants

pubmed: 31498851
doi: 10.1371/journal.pone.0222179
pii: PONE-D-18-08918
pmc: PMC6733457
doi:

Substances chimiques

G-protein-coupled receptor 40, rat 0
GW9508 0
Methylamines 0
Propionates 0
Receptors, G-Protein-Coupled 0
Myristoylated Alanine-Rich C Kinase Substrate 125267-21-2
Protein Kinase C-alpha EC 2.7.11.13
Protein Kinase C-epsilon EC 2.7.11.13
Glucose IY9XDZ35W2
Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0222179

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Mol Cell Endocrinol. 1999 Sep 10;155(1-2):61-8
pubmed: 10580839
J Pept Res. 2000 Feb;55(2):163-72
pubmed: 10784032
J Biol Chem. 2000 Aug 25;275(34):26449-57
pubmed: 10840037
Annu Rev Pharmacol Toxicol. 2001;41:145-74
pubmed: 11264454
Endocrinology. 2002 Nov;143(11):4203-9
pubmed: 12399413
J Biol Chem. 2003 Mar 28;278(13):11303-11
pubmed: 12496284
J Biol Chem. 2003 Mar 14;278(11):9896-904
pubmed: 12514176
Nature. 2003 Mar 13;422(6928):173-6
pubmed: 12629551
Pharmacol Toxicol. 2003 Jan;92(1):3-13
pubmed: 12710591
J Biol Chem. 2003 Nov 7;278(45):44753-7
pubmed: 12941947
Endocrinology. 1992 Jan;130(1):167-78
pubmed: 1370150
Diabetes. 2004 Jan;53(1):5-13
pubmed: 14693691
Drugs. 2004;64(12):1339-58
pubmed: 15200348
J Physiol. 2004 Nov 15;561(Pt 1):133-47
pubmed: 15388777
J Membr Biol. 2004 Jul 15;200(2):57-66
pubmed: 15520904
Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E670-7
pubmed: 15914509
Cell Tissue Res. 2005 Nov;322(2):207-15
pubmed: 16044321
Biochem Biophys Res Commun. 2005 Sep 16;335(1):97-104
pubmed: 16081037
Biochem Biophys Res Commun. 2005 Dec 30;338(4):1788-90
pubmed: 16289108
Curr Pharm Des. 2006;12(4):485-501
pubmed: 16472141
Diabetologia. 2006 May;49(5):962-8
pubmed: 16525841
Br J Pharmacol. 2006 Jul;148(5):619-28
pubmed: 16702987
Cell Signal. 2006 Sep;18(9):1360-5
pubmed: 16716567
Diabetologia. 2006 Jul;49(7):1578-86
pubmed: 16752176
J Clin Invest. 2006 Jul;116(7):1802-12
pubmed: 16823478
J Biol Chem. 2006 Sep 29;281(39):28499-507
pubmed: 16870611
Diabetes. 2006 Dec;55 Suppl 2:S16-23
pubmed: 17130640
Diabetes. 2007 Apr;56(4):1087-94
pubmed: 17395749
Expert Opin Ther Targets. 2007 May;11(5):661-71
pubmed: 17465724
Diabetes. 2008 Aug;57(8):2211-9
pubmed: 18477808
Biochim Biophys Acta. 2008 Oct;1783(10):1929-34
pubmed: 18486624
Pharmacol Rev. 2008 Dec;60(4):405-17
pubmed: 19047536
Nat Rev Drug Discov. 2009 May;8(5):369-85
pubmed: 19365392
Adv Exp Med Biol. 2010;654:91-114
pubmed: 20217496
FASEB J. 2013 Apr;27(4):1610-20
pubmed: 23299857
Diabetes. 2013 Oct;62(10):3316-23
pubmed: 23818527
Diabetes Res Clin Pract. 2014 Feb;103(2):137-49
pubmed: 24630390
Nature. 1989 Sep 21;341(6239):197-205
pubmed: 2550825
J Clin Invest. 2015 Dec;125(12):4714-28
pubmed: 26571400
Biochem J. 1989 Nov 15;264(1):27-33
pubmed: 2690823
Sci Rep. 2016 May 16;6:25912
pubmed: 27180622
J Biol Chem. 2016 Jul 15;291(29):14986-95
pubmed: 27226533
Pharmacol Res Perspect. 2016 Apr 27;4(3):e00237
pubmed: 27433346
FASEB J. 2017 Mar;31(3):1028-1045
pubmed: 27927723
Endocrinology. 1987 Sep;121(3):1025-33
pubmed: 3304975
Cancer Res. 1980 Oct;40(10):3827-31
pubmed: 6254641
Cell. 1995 Jan 27;80(2):259-68
pubmed: 7834745
J Biol Chem. 1993 Jan 25;268(3):1501-4
pubmed: 8420923
J Biol Chem. 1997 Jan 17;272(3):1417-20
pubmed: 8999804
Am J Physiol. 1997 Jan;272(1 Pt 1):C263-9
pubmed: 9038832
Biochem J. 1998 Jun 1;332 ( Pt 2):281-92
pubmed: 9601053
Trends Cell Biol. 1998 Feb;8(2):84-7
pubmed: 9695814
J Cell Biol. 1998 Oct 19;143(2):511-21
pubmed: 9786959

Auteurs

Takuya Hashimoto (T)

2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

Hideo Mogami (H)

Department of Health and Nutrition, Tokoha University, Shizuoka, Japan.

Daisuke Tsuriya (D)

2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

Hiroshi Morita (H)

2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

Shigekazu Sasaki (S)

2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

Tatsuro Kumada (T)

Department of Occupational Therapy, Tokoha University, Shizuoka, Japan.

Yuko Suzuki (Y)

Department of Medical Physiology, Hamamatsu University School of Medicine, Shizuoka, Japan.

Tetsumei Urano (T)

Department of Medical Physiology, Hamamatsu University School of Medicine, Shizuoka, Japan.

Yutaka Oki (Y)

2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.
Department of Family and Community Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

Takafumi Suda (T)

2nd Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH